skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1

Review

(1497) Views  (532) Full article downloads

Authors: Rolando M Viani

Published Date June 2010 Volume 2010:2 Pages 141 - 149
DOI: http://dx.doi.org/10.2147/HIV.S5854

Rolando M Viani

Department of Pediatrics, Division of Infectious Diseases, Center for AIDS Research, University of California San Diego School of Medicine and UCSD, Mother, Child and Adolescent HIV Program, Rady Children’s Hospital, San Diego, California, USA

Abstract: Etravirine is an oral diarylpyrimidine compound, a second-generation human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) with expanded antiviral activity against NNRTI-resistant HIV-1, to be used in combination therapy for treatment-experienced patients. Compared with first-generation NNRTIs, etravirine has a high genetic barrier to resistance, and is better tolerated without the neuropsychiatric and hepatic side effects of efavirenz and nevirapine, respectively. Its safety profile is comparable to placebo with the exception of rash, which has been mild and self-limited in the great majority of patients. In phase III clinical trials among treatment-experienced patients harboring NNRTI-resistant HIV-1, etravirine in combination with an optimized background regimen (OBR) that included ritonavir-boosted darunavir demonstrated superior antiviral activity than the control OBR. In addition, patients on the etravirine arm had fewer AIDS-defining conditions, hospitalizations, and lower mortality compared with the OBR control arm.

Keywords: HIV, antiretroviral therapy, non-nucleoside reverse transcriptase inhibitor








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The pathophysiology of bronchiectasis
The prevalence of human immunodeficiency virus infection among TB patients in Port Harcourt Nigeria
Is it safe? Talking to teens with HIV/AIDS about death and dying: a 3-month evaluation of Family Centered Advance Care (FACE) planning – anxiety, depression, quality of life
Long-term treatment of patients with HIV-1: the role of atazanavir
Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives?
Erratum
Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum